| 2019 |
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. |
Nature |
1770 |
31666701 |
| 2011 |
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. |
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research |
611 |
20593411 |
| 2006 |
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. |
The New England journal of medicine |
391 |
17050891 |
| 2018 |
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. |
Cancer discovery |
340 |
30254093 |
| 2004 |
AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. |
The Journal of pharmacology and experimental therapeutics |
325 |
15615864 |
| 2013 |
Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. |
Circulation |
283 |
24014831 |
| 2016 |
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. |
The Lancet. Neurology |
275 |
26879279 |
| 2006 |
AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. |
Cancer research |
262 |
16951187 |
| 2009 |
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology |
257 |
19786654 |
| 2020 |
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology |
250 |
31895611 |
| 1991 |
A deletion in the amelogenin gene (AMG) causes X-linked amelogenesis imperfecta (AIH1). |
Genomics |
245 |
1916828 |
| 2004 |
Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. |
Clinical pharmacology and therapeutics |
231 |
15592334 |
| 2015 |
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. |
Leukemia |
215 |
26239198 |
| 2009 |
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology |
203 |
19546406 |
| 2020 |
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. |
Clinical cancer research : an official journal of the American Association for Cancer Research |
200 |
33203642 |
| 2003 |
The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. |
Journal of the American Society of Nephrology : JASN |
199 |
12595492 |
| 2003 |
The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. |
Kidney international |
171 |
12472790 |
| 2017 |
First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors. |
Clinical cancer research : an official journal of the American Association for Cancer Research |
170 |
28655795 |
| 2015 |
Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor. |
The Journal of pharmacology and experimental therapeutics |
166 |
26559125 |
| 2013 |
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. |
Blood |
166 |
24300852 |
| 2012 |
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. |
Annals of oncology : official journal of the European Society for Medical Oncology |
166 |
22700995 |
| 2007 |
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology |
159 |
17557949 |
| 2013 |
Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. |
Blood |
146 |
24311721 |
| 2014 |
Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity. |
Cancer cell |
141 |
25043603 |
| 2010 |
Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. |
Molecular cancer therapeutics |
129 |
20937592 |
| 2015 |
The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents. |
Molecular cancer therapeutics |
127 |
25567130 |
| 2009 |
AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. |
Molecular cancer therapeutics |
120 |
19366899 |
| 2007 |
AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. |
Clinical cancer research : an official journal of the American Association for Cancer Research |
118 |
18006775 |
| 2014 |
Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. |
Molecular cancer therapeutics |
115 |
24674885 |
| 1992 |
Identification of a nonsense mutation in the amelogenin gene (AMELX) in a family with X-linked amelogenesis imperfecta (AIH1). |
Human genetics |
114 |
1483698 |
| 2019 |
Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release. |
Clinical cancer research : an official journal of the American Association for Cancer Research |
112 |
30918018 |
| 2019 |
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. |
Investigational new drugs |
108 |
31359240 |
| 2010 |
Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. |
Cancer research |
108 |
20935223 |
| 2020 |
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors. |
Journal for immunotherapy of cancer |
105 |
33046621 |
| 1995 |
Characterisation of molecular defects in X-linked amelogenesis imperfecta (AIH1). |
Human mutation |
102 |
7599636 |
| 2008 |
The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics. |
Journal of pharmaceutical sciences |
100 |
18214948 |
| 2014 |
Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer. |
Journal of medicinal chemistry |
94 |
24967612 |
| 2020 |
A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. |
Cephalalgia : an international journal of headache |
93 |
33231489 |
| 2012 |
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. |
Cancer |
92 |
22692704 |
| 2019 |
Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. |
Blood advances |
89 |
31253596 |
| 2024 |
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration. |
Annals of oncology : official journal of the European Society for Medical Oncology |
85 |
39293516 |
| 2015 |
AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. |
Molecular cancer therapeutics |
82 |
25931519 |
| 2011 |
AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. |
PloS one |
80 |
22087278 |
| 2012 |
Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. |
The Journal of allergy and clinical immunology |
79 |
23174659 |
| 2010 |
Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. |
Molecular cancer therapeutics |
75 |
20124448 |
| 2021 |
The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer. |
Clinical cancer research : an official journal of the American Association for Cancer Research |
73 |
33504551 |
| 2017 |
Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects. |
Pharmaceutical research |
71 |
28593473 |
| 2018 |
Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors. |
Journal for immunotherapy of cancer |
70 |
30253804 |
| 2000 |
Unique enamel phenotype associated with amelogenin gene (AMELX) codon 41 point mutation. |
Journal of dental research |
70 |
11005731 |
| 2015 |
T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330. |
Blood cancer journal |
69 |
26295610 |
| 2011 |
Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. |
The Journal of pharmacology and experimental therapeutics |
67 |
21385891 |
| 2020 |
AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing. |
Cell death discovery |
64 |
32655895 |
| 2015 |
Critical Cysteine Residues in Both the Calcium-Sensing Receptor and the Allosteric Activator AMG 416 Underlie the Mechanism of Action. |
Molecular pharmacology |
63 |
26290606 |
| 2014 |
Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3. |
Journal of medicinal chemistry |
63 |
24641103 |
| 2025 |
AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers. |
Cancer discovery |
58 |
39282709 |
| 2015 |
Evolocumab (AMG 145) for primary hypercholesterolemia. |
Expert review of cardiovascular therapy |
58 |
25824308 |
| 2017 |
Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis. |
Lupus science & medicine |
57 |
29018537 |
| 2012 |
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. |
Annals of oncology : official journal of the European Society for Medical Oncology |
55 |
23108953 |
| 2010 |
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. |
BJU international |
55 |
21156020 |
| 2020 |
The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. |
Blood advances |
54 |
32898244 |
| 2015 |
The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk. |
PloS one |
53 |
26305211 |
| 2013 |
Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects. |
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association |
53 |
24235081 |
| 2013 |
AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. |
Kidney international |
51 |
23903371 |
| 2012 |
MBL2, MASP2, AMELX, and ENAM gene polymorphisms and dental caries in Polish children. |
Oral diseases |
50 |
22221294 |
| 2020 |
AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia. |
Clinical cancer research : an official journal of the American Association for Cancer Research |
49 |
31937611 |
| 2015 |
Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study. |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology |
48 |
26304872 |
| 2015 |
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. |
Arthritis research & therapy |
47 |
26290435 |
| 2013 |
AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models. |
Molecular cancer therapeutics |
46 |
23990115 |
| 2019 |
Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII. |
Cancer chemotherapy and pharmacology |
45 |
31154523 |
| 2016 |
In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models. |
Molecular cancer therapeutics |
45 |
27196782 |
| 2024 |
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer. |
Cancer discovery |
44 |
37861452 |
| 2010 |
Association between AMELX polymorphisms and dental caries in Koreans. |
Oral diseases |
44 |
21114591 |
| 2019 |
89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake. |
Clinical cancer research : an official journal of the American Association for Cancer Research |
43 |
30745297 |
| 2014 |
Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy. |
Clinical cancer research : an official journal of the American Association for Cancer Research |
43 |
24727326 |
| 2015 |
Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. |
Breast (Edinburgh, Scotland) |
42 |
25747197 |
| 2010 |
AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. |
Current opinion in molecular therapeutics |
42 |
20677100 |
| 2020 |
AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. |
Blood advances |
41 |
32886754 |
| 2010 |
Effect of calcium and the calcimimetic AMG 641 on matrix-Gla protein in vascular smooth muscle cells. |
Calcified tissue international |
41 |
21161195 |
| 2021 |
Spotlight on Sotorasib (AMG 510) for KRAS G12C Positive Non-Small Cell Lung Cancer. |
Lung Cancer (Auckland, N.Z.) |
40 |
34675734 |
| 2015 |
AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes. |
Diabetes, obesity & metabolism |
40 |
26434934 |
| 2014 |
Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-γ IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. |
Pharmaceutical research |
40 |
25213774 |
| 2019 |
AMG 510 First to Inhibit "Undruggable" KRAS. |
Cancer discovery |
39 |
31189530 |
| 2018 |
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. |
Investigational new drugs |
39 |
29980894 |
| 2016 |
Enamel ribbons, surface nodules, and octacalcium phosphate in C57BL/6 Amelx mice and Amelx lyonization. |
Molecular genetics & genomic medicine |
39 |
27896287 |
| 2014 |
Inhibitors of β-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-2'-amine (AMG-8718). |
Journal of medicinal chemistry |
37 |
25363711 |
| 2009 |
The calcimimetic AMG 641 accelerates regression of extraosseous calcification in uremic rats. |
American journal of physiology. Renal physiology |
37 |
19321594 |
| 2015 |
Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines. |
Journal of medicinal chemistry |
36 |
25970324 |
| 2010 |
A mutation in the mouse Amelx tri-tyrosyl domain results in impaired secretion of amelogenin and phenocopies human X-linked amelogenesis imperfecta. |
Human molecular genetics |
36 |
20067920 |
| 1993 |
Technical aspects of acoustic myography (AMG) of human skeletal muscle: contact pressure and force/AMG relationships. |
Journal of neuroscience methods |
36 |
8321016 |
| 2014 |
Alteration of conserved alternative splicing in AMELX causes enamel defects. |
Journal of dental research |
35 |
25117480 |
| 2023 |
Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC). |
Journal of clinical pharmacology |
34 |
37694295 |
| 2017 |
Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. |
Cancer |
34 |
28472537 |
| 2012 |
Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme. |
Drug metabolism and disposition: the biological fate of chemicals |
34 |
22517972 |
| 2010 |
Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis. |
Expert opinion on biological therapy |
34 |
21114421 |
| 2014 |
Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia. |
Molecular cancer therapeutics |
33 |
24526162 |
| 2020 |
KRAS(G12C)-AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations. |
Scientific reports |
32 |
32686745 |
| 2017 |
A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia. |
American journal of hematology |
31 |
28370201 |
| 2013 |
A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. |
Gynecologic oncology |
31 |
24361733 |
| 2019 |
Erenumab (AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries. |
Cephalalgia : an international journal of headache |
30 |
31366221 |
| 2014 |
Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases. |
British journal of clinical pharmacology |
30 |
24803302 |